Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity

Cancer Immunology, Immunotherapy

Volumn 57, Issue 3, 2008, Pages 379-388

  Liljefors, Maria ^a   Nilsson, Bo ^a   Mellstedt, Håkan ^a   Frödin, Jan Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ADCC; GM CSF; Immunotherapy; Pharmacokinetics

Indexed keywords

RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFECT; EOSINOPHIL COUNT; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; METASTASIS; MONOCYTE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PRIORITY JOURNAL; REPEATED DRUG DOSE; TREATMENT DURATION;

ADULT; AGED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL ADHESION MOLECULES; CELL PROLIFERATION; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MIDDLE AGED; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 37349070995     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0377-1     Document Type: Article

References (39)

1. Armitage JO (1998) Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92(12):4491-4508
2. Aweeka FT, Kwong M, Mak M, al-Uzri A, Affrime M, Cutler D, Kahn J, Gambertoglio JG (1996) Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor: the effects of zidovudine. J Clin Pharmacol 36(12):1107-1113
3. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23(11):2445-2459
4. Bukowski RM, Budd GT, Gibbons JA, Bauer RJ, Childs A, Antal J, Finke J, uason L, Lorenzi V, McLain D, et al (1994) Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects. J Clin Oncol 12(1):97-106
5. Burgess AW, Begley CG, Johnson GR, Lopez AF, Williamson DJ, Mermod JJ, Simpson RJ, Schmitz A, DeLamarter JF (1987) Purification and properties of bacterially synthesized human granulocyte-macrophage colony stimulating factor. Blood 69(1):43-51
6. Cannistra SA, Groshek P, Garlick R, Miller J, Griffin JD (1990) Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells. Proc Natl Acad Sci U S A 87(1):93-97
7. Cebon J, Dempsey P, Fox R, Kannourakis G, Bonnem E, Burgess AW, Morstyn G (1988) Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay. Blood 72(4):1340-1347
8. Cebon JS, Bury RW, Lieschke GJ, Morstyn G (1990) The effects of dose and route of administration on the pharmacokinetics of granulocyte-macrophage colony-stimulating factor. Eur J Cancer 26(10):1064-1069
9. Chachoua A, Oratz R, Hoogmoed R, Caron D, Peace D, Liebes L, Blum RH, Vilcek J (1994) Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. J Immunother Emphasis Tumor Immunol 15(3):217-224
10. Collins TS, Hurwitz HI (2005) Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 32(1):61-68
11. Gregory B, Kirchem A, Phipps S, Gevaert P, Pridgeon C, Rankin SM, Robinson DS (2003) Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Immunol 170(11):5359-5366
12. Gribben JG, Devereux S, Thomas NS, Keim M, Jones HM, Goldstone AH, Linch DC (1990) Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335(8687):434-437
13. Hellman C, Lonnkvist K, Hedlin G, Hallden G, Lundahl J (2002) Down-regulated IL-5 receptor expression on peripheral blood eosinophils from budesonide-treated children with asthma. Allergy 57(4):323-328
14. Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A 76(3):1438-1442
15. Hovgaard D, Mortensen BT, Schifter S, Nissen NI (1993) Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor. Eur J Haematol 50(1):32-36
16. Kuwabara T, Kobayashi S, Sugiyama Y (1996) Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab Rev 28(4):625-658
17. Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 327(2):99-106
18. Liljefors M, Nilsson B, Fagerberg J, Ragnhammar P, Mellstedt H, Frodin J-E (2005) Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Int J Oncol 26(6):1581-1589
19. Liljefors M, Ragnhammar P, Nilsson B, Ullenhag G, Mellstedt H, Frodin J-E (2004) Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Int J Oncol 25(3):703-711
20. Martinez-Moczygemba M, Huston DP (2003) Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 112(4):653-665; quiz 666
21. Masucci G, Wersall P, Ragnhammar P, Mellstedt H (1989) Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 29(4):288-292
22. Mellstedt H (2003) Monoclonal antibodies in human cancer. Drugs Today (Barc) 39(Suppl C):1-16
23. Mellstedt H, Fagerberg J, Frodin J-E, Henriksson L, Hjelm-Skog A-L, Liljefors M, Ragnhammar P, Shetye J, Osterborg A (1999) Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr Opin Hematol 6(3):169-175
24. Metcalf D, Nicola NA, Mifsud S, Di Rago L (1999) Receptor clearance obscures the magnitude of granulocyte-macrophage colony-stimulating factor responses in mice to endotoxin or local infections. Blood 93(5):1579-1585
25. Molineux G (2004) The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 10(11):1235-1244
26. Muller CE, Mukodzi S, Reddemann H (1999) Relationships of cytokine (GM-CSF) serum concentration to blood cell count and the inflammatory parameters in children with malignant diseases. Pediatr Hematol Oncol 16(6):509-518
27. Pardoll DM (2000) Therapeutic vaccination for cancer. Clin Immunol 95(1 Pt 2):S44-S62
28. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L (2007) Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18:226-232
29. Ragnhammar P, Masucci G, Frodin J-E, Hjelm A-L, Mellstedt H (1992) Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor. Cancer Immunol Immunother 35(3):158-164
30. Ragnhammar P, Fagerberg J, Frodin J-E, Hjelm A-L, Lindemalm C, Magnusson I, Masucci G, Mellstedt H (1993) Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma-long-lasting, complete remissions can be induced. Int J Cancer 53(5):751-758
31. Ragnhammar P, Friesen HJ, Frodin J-E, Lefvert AK, Hassan M, Osterborg A, Mellstedt H (1994) Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 84(12):4078-4087
32. Ragnhammar P, Frodin J-E, Trotta PP, Mellstedt H (1994) Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony- stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol Immunother 39(4):254-262
33. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I (2004) High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64(17):6337-6343
34. Shaw DR, Khazaeli MB, Sun LK, Ghrayeb J, Daddona PE, McKinney S, LoBuglio AF (1987) Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. J Immunol 138(12):4534-4538
35. Stute N, Furman WL, Schell M, Evans WE (1995) Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. J Pharm Sci 84(7):824-828
36. Thompson JA, Lee DJ, Kidd P, Rubin E, Kaufmann J, Bonnem EM, Fefer A (1989) Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 7(5):629-637
37. Ullenhag G, Bird C, Ragnhammar P, Frodin J-E, Strigard K, Osterborg A, Thorpe R, Mellstedt H, Wadhwa M (2001) Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Clin Immunol 99(1):65-74
38. Wadhwa M, Skog A-L, Bird C, Ragnhammar P, Liljefors M, Gaines-Das R, Mellstedt H, Thorpe R (1999) Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 5(6):1353-1361
39. Weiner GJ, Link BK (2004) Antibody therapy of lymphoma. Adv Pharmacol 51:229-253